Journal of Gastroenterology and Hepatology · 2016 · 38 citations · 15 references
MedicineHematologyOncologyCarcinogenesisHepatologyMolecular OncologyChronic Liver DiseaseHepatic Function TestingHepatocellular CarcinomaLiver DiseaseLiver Function TestsViral HepatitisChronic Hepatitis B - Associated CarcinomaChronic Viral HepatitisHepatic BiomarkersLiver BiomarkersLiver Disease PrognosisLiver Disease Risk AssessmentLiver Fibrosis BiomarkersLiver Fibrosis Staging
BACKGROUND AND AIM: Gamma-glutamyl transpeptidase-to-platelet ratio (GPR) can evaluate the degree of liver fibrosis. We investigated whether GPR can predict the development of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients. METHODS: We retrospectively evaluated 1109 CHB patients that were enrolled between 2006 and 2012, and all patients had available data for the assessment of GPR at enrollment. Three risk groups were defined according to tertile stratification: GPR < 0.05, low-risk (n = 370 [33.4%]); GPR 0.05-0.24, intermediate-risk (n = 370 [33.4%]); and GPR > 0.24, high-risk (n = 369 [33.2%]). The predictive accuracy of GPR, fibrosis-4 (FIB-4), and aspartate transaminase-to-platelet ratio index (APRI) in predicting HCC development was tested. RESULTS: The median age of the study population (746 men and 363 women) was 50 years. During the follow-up period (median, 32 months; interquartile range, 19-57 months), 69 (6.2%) patients developed HCC. Together with age, male gender, diabetes mellitus, antiviral therapy, serum albumin, and alpha-fetoprotein, the relative risk of HCC development significantly increased from low-risk to high-risk GPR groups (hazard ratio [HR], up to 29.5; adjusted HR, up to 10.6; all P < 0.05). In addition, FIB-4 was calculated to be a significantly high relative risk of HCC development (HR, up to 20.1; adjusted HR, up to 7.3; all P < 0.05), whereas APRI was not (P = 0.168). The cumulative incidence of HCC development was significantly different among three risk groups (P < 0.001, log-rank test). CONCLUSIONS: This study suggests that GPR can be used as a noninvasive marker to assess the risk of HCC development in CHB patients.
15
AASLD guidelines for treatment of chronic hepatitis B
Norah A. Terrault, Natalie Bzowej, Kyong‐Mi Chang et al. · Hepatology · 2015 · 2K citations
Maud Lemoine, Yusuke Shimakawa, Shevanthi Nayagam et al. · Gut · 2015 · 365 citations · Full text
Hye Won Lee, Eun Jin Yoo, Beom Kyung Kim et al. · The American Journal of Gastroenterology · 2014 · 154 citations · Full text